Literature DB >> 29722454

Elephants, Parkinson's Disease, and Proof-of-Concept Clinical Trials.

Jesse M Cedarbaum1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29722454     DOI: 10.1002/mds.27398

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


× No keyword cloud information.
  6 in total

Review 1.  Innovative Approaches for Slowing Disease Progression in Parkinson's Disease: Takeaways from the 14th Annual International Society for Central Nervous System Clinical Trials and Methodology Scientific Meeting.

Authors:  Monica Javidnia; Mark Frasier; Ira Shoulson; Ibrahim Turkoz; Kumar Budur
Journal:  Innov Clin Neurosci       Date:  2020-01-01

Review 2.  Disease modification and biomarker development in Parkinson disease: Revision or reconstruction?

Authors:  Alberto J Espay; Lorraine V Kalia; Ziv Gan-Or; Caroline H Williams-Gray; Philippe L Bedard; Steven M Rowe; Francesca Morgante; Alfonso Fasano; Benjamin Stecher; Marcelo A Kauffman; Matthew J Farrer; Chris S Coffey; Michael A Schwarzschild; Todd Sherer; Ronald B Postuma; Antonio P Strafella; Andrew B Singleton; Roger A Barker; Karl Kieburtz; C Warren Olanow; Andres Lozano; Jeffrey H Kordower; Jesse M Cedarbaum; Patrik Brundin; David G Standaert; Anthony E Lang
Journal:  Neurology       Date:  2020-02-26       Impact factor: 9.910

Review 3.  Targeted Therapies for Parkinson's Disease: From Genetics to the Clinic.

Authors:  S Pablo Sardi; Jesse M Cedarbaum; Patrik Brundin
Journal:  Mov Disord       Date:  2018-04-27       Impact factor: 10.338

Review 4.  Parkinson Diseases in the 2020s and Beyond: Replacing Clinico-Pathologic Convergence With Systems Biology Divergence.

Authors:  Alberto J Espay; Anthony E Lang
Journal:  J Parkinsons Dis       Date:  2018       Impact factor: 5.568

5.  The Qualification of an Enrichment Biomarker for Clinical Trials Targeting Early Stages of Parkinson's Disease.

Authors:  Diane Stephenson; Derek Hill; Jesse M Cedarbaum; Maria Tome; Spiros Vamvakas; Klaus Romero; Daniela J Conrado; David T Dexter; John Seibyl; Danna Jennings; Timothy Nicholas; Dawn Matthews; Zhiyong Xie; Syed Imam; Paul Maguire; David Russell; Mark Forrest Gordon; Glenn T Stebbins; Ed Somer; Jill Gallagher; Arthur Roach; Peter Basseches; Donald Grosset; Kenneth Marek
Journal:  J Parkinsons Dis       Date:  2019       Impact factor: 5.568

Review 6.  Novel targeted therapies for Parkinson's disease.

Authors:  Theodora Ntetsika; Paraskevi-Evita Papathoma; Ioanna Markaki
Journal:  Mol Med       Date:  2021-02-25       Impact factor: 6.354

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.